Daiichi Sankyo Halts Development of mPBD Platform ADC
More Than Five Cases of Big Pharma ADC Development Halts and Delays in Past Year
"Biotechs with Proprietary Platforms Face a Test of Their Technological Competitiveness"

Global big pharma companies are facing a series of setbacks in the development of new ADC (antibody-drug conjugate) anticancer drugs, which have been called a "game changer" in the oncology market. As development of major candidates has been halted and clinical trials delayed over the past year or so, some analysts say ADC technology has entered a full-fledged phase of validation.

Big Pharma Cannot Escape ADC Validation Phase...Will It Be an Opportunity for K-Bio? View original image

According to the bio industry on February 4, Daiichi Sankyo, which is credited with reshaping the ADC market with its blockbuster anticancer drug Enhertu, announced at the end of last month in its quarterly earnings release that it had halted development of the ADC candidate "DS-9606." Although it was the first drug candidate to apply the company’s next-generation ADC platform, the "mPBD technology," it remains unclear whether development will resume.


From January last year to early this year, there have been at least five publicly confirmed cases of ADC development discontinuations or clinical delays at global pharmaceutical companies. Datroway, a TROP2-targeting ADC that Daiichi Sankyo is co-developing with AstraZeneca (AZ), has experienced a schedule delay. The announcement of phase 3 clinical trial results in non-small cell lung cancer patients, initially expected in 2025, has recently been pushed back to the second half of 2026. In addition, I-DXd, a B7-H3-targeting ADC, was at one point placed on clinical hold by the U.S. Food and Drug Administration (FDA) after a suspected treatment-related death was reported during the clinical process.


The situation is no easier for other big pharma companies that have jumped into ADC drug development. Pfizer has halted development of "Felmetatumab vedotin," a B7-H4-targeting ADC it acquired through its purchase of Seagen last year. The company judged that this candidate was unlikely to show meaningful improvement over existing standard treatments in solid tumors such as triple-negative breast cancer (TNBC). ADC Therapeutics, a biotech specializing in ADCs, also discontinued development of its CD22-targeting ADC last year as part of a pipeline restructuring.


Despite last year’s setbacks, global pharmaceutical companies’ interest in ADCs has not waned. The first major deal concluded after this year’s JP Morgan Healthcare Conference, the largest event in the bio industry, was an agreement under which AbbVie licensed a bispecific ADC from Chinese biotech Remegen for up to 5.6 billion dollars (about 8 trillion won).


Industry observers say the recent wave of ADC development discontinuations and delays reflects a shift from a phase of indiscriminate expansion to a more sophisticated stage of technological competition.

An ADC researcher at a Korean institution said, "In the past, simply having the 'aiming' function to hit a specific target drew attention, but now the field has moved into a high-level technology validation stage that asks how safely you can deliver the drug inside the cell (the linker) and how you overcome resistance (the payload)," adding, "Only companies with strong development capabilities will succeed in new drug development."


There is also an assessment that this so-called "ADC technology validation phase" could present an opportunity for Korean biotech companies. This is because domestic firms are pursuing differentiated approaches based on their own platform technologies in areas where global big pharma has struggled.



Ligachem Bio, regarded as a leading Korean player in ADC drug development, is continuing development with a different platform strategy that applies its own linker and payload design, while targeting the same B7-H4 target as the ADC for which Pfizer halted development. Since the failure of a specific candidate does not automatically mean that the target itself has fundamental limitations, this suggests that the technological competitiveness of Korean companies is being put to the test in areas where global firms have faltered.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing